^
Association details:
| Biomarker: | SSTR2 overexpression |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Actinium-225 DOTATATE (RYZ101) (α radiation emission, SSTR2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RYZ101 (Ac-225 DOTATATE) Opportunity Beyond Gastroenteropancreatic Neuroendocrine Tumors: Preclinical Efficacy in Small Cell Lung Cancer
Published date:
08/24/2023
Excerpt:
In multiple SSTR2-expressing SCLC xenograft models, single-dose intravenous RYZ101 3 uCi (0.111 MBq) or 4 uCi (0.148 MBq) significantly inhibited tumor growth, with deeper responses, including sustained regression, observed in the models with higher SSTR2 levels.
DOI:
10.1158/1535-7163.MCT-23-0029
Source:
Title:
RYZ101 (Ac-225 DOTATATE) Opportunity Beyond GEP-NETs: Preclinical Efficacy in Small Cell Lung Cancer
Published date:
08/08/2023
Excerpt:
In multiple SCLC xenograft models, RYZ101 significantly inhibited tumor growth and prolonged survival, with deeper responses, including sustained regression, observed in the models with higher SSTR2 level. The anti-tumor effect was further enhanced when combining RYZ101 with carboplatin and etoposide at clinically relevant doses...Preclinical data demonstrate the potential of RYZ101 for the treatment of patients with SSTR+ SCLC.
Secondary therapy:
carboplatin + etoposide IV
Source:
Title:
5042 / 9 - Anti-tumor activity of RYZ101 (Ac-225 DOTATATE) in somatostatin receptor-expressing preclinical models of small-cell lung cancer
Published date:
03/15/2023
Excerpt:
In multiple SCLC xenograft models, RYZ101 significantly inhibited tumor growth and prolonged survival, with deeper responses, including sustained regression, observed in the models with higher SSTR2 level. The anti-tumor effect was further enhanced when combining RYZ101 with carboplatin and etoposide at clinically relevant doses....In summary, RYZ101 is a first-in-class, highly potent, α-emitting radiopharmaceutical therapy being developed for the treatment of SSTR+ solid tumors. Preclinical data demonstrate the potential of RYZ101 for the treatment of patients with SSTR+ SCLC.
Secondary therapy:
carboplatin + etoposide IV
